Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 55.515 USD -0.05% Market Closed
Market Cap: 3.2B USD
Have any thoughts about
Agios Pharmaceuticals Inc?
Write Note

Intrinsic Value

AGIO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one AGIO stock under the Base Case scenario is 18.811 USD. Compared to the current market price of 55.515 USD, Agios Pharmaceuticals Inc is Overvalued by 66%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AGIO Intrinsic Value
18.811 USD
Overvaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Agios Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AGIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AGIO?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Agios Pharmaceuticals Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Agios Pharmaceuticals Inc

Provide an overview of the primary business activities
of Agios Pharmaceuticals Inc.

What unique competitive advantages
does Agios Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Agios Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Agios Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Agios Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Agios Pharmaceuticals Inc.

Provide P/S
for Agios Pharmaceuticals Inc.

Provide P/E
for Agios Pharmaceuticals Inc.

Provide P/OCF
for Agios Pharmaceuticals Inc.

Provide P/FCFE
for Agios Pharmaceuticals Inc.

Provide P/B
for Agios Pharmaceuticals Inc.

Provide EV/S
for Agios Pharmaceuticals Inc.

Provide EV/GP
for Agios Pharmaceuticals Inc.

Provide EV/EBITDA
for Agios Pharmaceuticals Inc.

Provide EV/EBIT
for Agios Pharmaceuticals Inc.

Provide EV/OCF
for Agios Pharmaceuticals Inc.

Provide EV/FCFF
for Agios Pharmaceuticals Inc.

Provide EV/IC
for Agios Pharmaceuticals Inc.

Show me price targets
for Agios Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Agios Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Agios Pharmaceuticals Inc?

What are the Net Income projections
for Agios Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Agios Pharmaceuticals Inc?

What are the EPS projections
for Agios Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Agios Pharmaceuticals Inc?

What are the EBIT projections
for Agios Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Agios Pharmaceuticals Inc?

Compare the revenue forecasts
for Agios Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Agios Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Agios Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Agios Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Agios Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Agios Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Agios Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Agios Pharmaceuticals Inc.

Provide ROE
for Agios Pharmaceuticals Inc.

Provide ROA
for Agios Pharmaceuticals Inc.

Provide ROIC
for Agios Pharmaceuticals Inc.

Provide ROCE
for Agios Pharmaceuticals Inc.

Provide Gross Margin
for Agios Pharmaceuticals Inc.

Provide Operating Margin
for Agios Pharmaceuticals Inc.

Provide Net Margin
for Agios Pharmaceuticals Inc.

Provide FCF Margin
for Agios Pharmaceuticals Inc.

Show all solvency ratios
for Agios Pharmaceuticals Inc.

Provide D/E Ratio
for Agios Pharmaceuticals Inc.

Provide D/A Ratio
for Agios Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Agios Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Agios Pharmaceuticals Inc.

Provide Quick Ratio
for Agios Pharmaceuticals Inc.

Provide Current Ratio
for Agios Pharmaceuticals Inc.

Provide Cash Ratio
for Agios Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Agios Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Agios Pharmaceuticals Inc?

What is the current Free Cash Flow
of Agios Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Agios Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Agios Pharmaceuticals Inc

Current Assets 1.1B
Cash & Short-Term Investments 1B
Receivables 3.1m
Other Current Assets 66.3m
Non-Current Assets 717.6m
Long-Term Investments 655.9m
PP&E 57.7m
Other Non-Current Assets 4.1m
Current Liabilities 119.5m
Accounts Payable 17.1m
Accrued Liabilities 49.6m
Other Current Liabilities 52.7m
Non-Current Liabilities 45.7m
Other Non-Current Liabilities 45.7m
Efficiency

Earnings Waterfall
Agios Pharmaceuticals Inc

Revenue
32.9m USD
Cost of Revenue
-3.5m USD
Gross Profit
29.4m USD
Operating Expenses
-436.4m USD
Operating Income
-407m USD
Other Expenses
1.1B USD
Net Income
674.3m USD

Free Cash Flow Analysis
Agios Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Agios achieved $9 million in net revenue from PYRUKYND, marking a 22% increase year-over-year. The company noted muted growth ahead, with focus on launching in thalassemia by 2025. They also received $1.1 billion in milestone payments following FDA approval of vorasidenib, enhancing their strong cash position of approximately $1.7 billion. Agios aims to file for expanded indications in thalassemia by year-end and has completed enrollment for the Phase III RISE UP study for sickle cell disease, targeting therapeutic launches in 2026. They remain committed to cost-effective strategies while preparing for significant market opportunities.

What is Earnings Call?
Fundamental Scores

AGIO Profitability Score
Profitability Due Diligence

Agios Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional ROE
ROIC is Increasing
42/100
Profitability
Score

Agios Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

AGIO Solvency Score
Solvency Due Diligence

Agios Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Agios Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGIO Price Targets Summary
Agios Pharmaceuticals Inc

Wall Street analysts forecast AGIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGIO is 56.1 USD with a low forecast of 51.51 USD and a high forecast of 59.85 USD.

Lowest
Price Target
51.51 USD
7% Downside
Average
Price Target
56.1 USD
1% Upside
Highest
Price Target
59.85 USD
8% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AGIO?

Click here to dive deeper.

Dividends

Agios Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AGIO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AGIO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

AGIO News

Other Videos

Profile

Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.2B USD

Dividend Yield

0%

Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 390 full-time employees. The company went IPO on 2013-07-24. The firm's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The firm is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

Contact

MASSACHUSETTS
Cambridge
88 Sidney St
+16176498600.0
www.agios.com

IPO

2013-07-24

Employees

390

Officers

CEO & Director
Mr. Brian M. Goff M.B.A.
Chief Financial Officer
Ms. Cecilia Jones
Corporate Secretary & Chief Legal Officer
Mr. James William Burns
Chief Medical Officer and Head of Research & Development
Dr. Sarah Gheuens M.D., Ph.D.
Chief Commercial Officer
Ms. Tsveta Milanova
Founder
Dr. Shin-San Su Ph.D.
Show More
VP, Controller & Principal Accounting Officer
Mr. T. J. Washburn
Show Less

See Also

Discover More
What is the Intrinsic Value of one AGIO stock?

The intrinsic value of one AGIO stock under the Base Case scenario is 18.811 USD.

Is AGIO stock undervalued or overvalued?

Compared to the current market price of 55.515 USD, Agios Pharmaceuticals Inc is Overvalued by 66%.

Back to Top